Tenax Therapeutics Inc expected to post a loss of 13 cents a share - Earnings Preview

Tenax Therapeutics

12/11/2021 12:05

* Tenax Therapeutics Inc  TENX.OQ   TENX.O  is expected to show
no change in quarterly revenue when it reports  results on
November 15 (estimated). 
​* Refinitiv's mean analyst estimate for Tenax Therapeutics Inc
is for a loss of 13 cents per share. For the same quarter last
year, the company reported a loss of 18 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Tenax
Therapeutics Inc is $4.75​, about 70.3% above​ its last closing
price of $1.41. ​​​
This summary was machine generated November 12 at 12:05 GMT. 
All figures in US dollars  unless otherwise stated